SCHEMBL1068756

SCHEMBL1068756

CCOC(=O)/C=C(/C)Oc1cccc(Br)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.47
ALDH1A1 P00352 5/20 0.47
TSHR P16473 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
CYP1A2 P05177 2/20 0.44
GAA P10253 1/20 0.44
RECQL P46063 1/20 0.44
KMT2A Q03164 4/20 0.43
KDM4E B2RXH2 3/20 0.40
LMNA P02545 2/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAOB P27338 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
POLB P06746 1/20 0.38
PKM P14618 1/20 0.38
RAB9A P51151 1/20 0.38
GALK1 P51570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1068753 1.00 MAPT (0.47) MAPTALDH1A1TSHRNPSR1CYP1A2
SCHEMBL1068757 1.00 MAPT (0.47) MAPTALDH1A1TSHRNPSR1CYP1A2
SCHEMBL1067677 0.86 LMNA (0.57) MAPTALDH1A1GAAKMT2AKDM4E
SCHEMBL1067680 0.86 LMNA (0.57) MAPTALDH1A1GAAKMT2AKDM4E
SCHEMBL1067679 0.86 LMNA (0.57) MAPTALDH1A1GAAKMT2AKDM4E
SCHEMBL1069254 0.84 ALDH1A1 (0.46) MAPTALDH1A1TSHRRECQLKMT2A
SCHEMBL1064148 0.84 ALDH1A1 (0.48) MAPTALDH1A1TSHRCYP1A2LMNA
SCHEMBL1069256 0.84 ALDH1A1 (0.46) MAPTALDH1A1TSHRRECQLKMT2A
SCHEMBL1064150 0.84 ALDH1A1 (0.48) MAPTALDH1A1TSHRCYP1A2LMNA
SCHEMBL1067349 0.84 ALDH1A1 (0.48) MAPTALDH1A1TSHRCYP1A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 MAPT 4151/4885ALDH1A1 1129/4885TSHR 3084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.